TG Therapeutics | TGTX - Cash And Equivalent


TG Therapeutics reported $612.25M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
AbbVie USD 6.57B 2.82B Jun/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Amgen USD 13.99B 1.95B Jun/2026
Ardelyx USD 31.21M 36.79M Mar/2026
Arrowhead Research USD 147.53M 54.11M Mar/2026
Bayer EUR 5.73B 943M Mar/2026
Biogen USD 1.28B 2.1B Jun/2026
Corcept Therapeutics USD 111.04M 2.3M Jun/2026
Curis USD 10.14M 10.14M Jun/2025
Gilead Sciences USD 7.63B 64M Mar/2026
J&J USD 20.42B 1.27B Jun/2026
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026
Novartis USD 7.62B 739M Jun/2026
Novavax USD 191.46M 36.9M Jun/2026
PTC Therapeutics USD 1.05B 215.9M Jun/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
TG Therapeutics USD 612.25M 170.04M Jun/2026
Verastem USD 181.68M 23.31M Mar/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026